BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20023417)

  • 1. KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer.
    Rokhlin OW; Guseva NV; Taghiyev AF; Glover RA; Cohen MB
    Cancer Biol Ther; 2010 Feb; 9(3):224-35. PubMed ID: 20023417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival.
    Rokhlin OW; Taghiyev AF; Bayer KU; Bumcrot D; Koteliansk VE; Glover RA; Cohen MB
    Cancer Biol Ther; 2007 May; 6(5):732-42. PubMed ID: 17387273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
    Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
    Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
    Cohen MB; Rokhlin OW
    J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
    Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
    Yoo J; Park SS; Lee YJ
    J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
    Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
    Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
    Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
    Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells.
    Wu W; Karelia D; Pramanik K; Amin SG; Sharma AK; Jiang C; Lu J
    Mol Carcinog; 2018 Aug; 57(8):1055-1066. PubMed ID: 29668110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
    Kim SM; Park JH; Kim KD; Nam D; Shim BS; Kim SH; Ahn KS; Choi SH; Ahn KS
    Phytother Res; 2014 Mar; 28(3):423-31. PubMed ID: 23686889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway.
    Li X; Song Y; Zhang P; Zhu H; Chen L; Xiao Y; Xing Y
    Tumour Biol; 2016 Jun; 37(6):7599-613. PubMed ID: 26687646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
    Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
    Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
    J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer.
    Shankar S; Srivastava RK
    Int J Oncol; 2007 Apr; 30(4):905-18. PubMed ID: 17332930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status.
    Guseva NV; Rokhlin OW; Glover RA; Cohen MB
    Cancer Biol Ther; 2011 Jul; 12(1):80-5. PubMed ID: 21525791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.